ANDA 202179, held by Rising. Prednisolone Sodium Phosphate.
As of Nov 16, 2026, ANDA 202179 (Prednisolone Sodium Phosphate), held by Rising, was first approved by FDA on Apr 10, 2013, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Apr 10, 2013 | Original application | Approved | None posted |
| Prednisolone Sodium PhosphateEQ 10MG BASE · tablet, orally disintegrating;oral | Prednisolone Sodium Phosphate | Discontinued |
| Prednisolone Sodium PhosphateEQ 15MG BASE · tablet, orally disintegrating;oral | Prednisolone Sodium Phosphate | Discontinued |
| Prednisolone Sodium PhosphateEQ 30MG BASE · tablet, orally disintegrating;oral | Prednisolone Sodium Phosphate | Discontinued |
| Dec 13, 2023 | Supplement 2Labeling · Standard review | Approved | None posted |
| Apr 10, 2013 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters